Secukinumab versus guselkumab in the complete treatment of ustekinumab‑resistant psoriatic plaques: ARROW

ABSTRACT: To investigate the clinical and molecular effects of direct IL-17A versus selective IL-23 inhibition in patients with anti-IL-12/23 refractory psoriatic plaques.

ORGANISM(S): Homo sapiens

PROVIDER: GSE197056 | GEO | 2023/06/21

REPOSITORIES: GEO